Artificial Hip And Knee Joint Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

Artificial Hip And Knee Joints Market Summary
Introduction
Artificial hip and knee joints are prosthetic implants designed to replace damaged joints, primarily addressing osteoarthritis, which affects over 528 million people globally, and other conditions like rheumatoid arthritis and traumatic fractures. The market is driven by an aging population, with 14.27% of China’s population over 65 in 2023, and increasing joint replacement needs, including over 700,000 knee replacements annually in the U.S. Innovations like robotic surgery and durable materials enhance outcomes. The global market is projected to reach between USD 7.2 billion and USD 10.5 billion in 2025, with a CAGR of 2.8% to 4.7% through 2030.

Regional Analysis
North America: The U.S. leads with high replacement volumes, while Canada focuses on elderly care.
Europe: Germany, France, and the UK dominate, driven by aging demographics.
Asia Pacific: China and India see growth due to rising osteoarthritis, while Japan targets elderly joint health.
Rest of the World: Brazil expands orthopedic care, and the Middle East invests in premium implants.

Application Analysis
Hospitals & Surgery Centers: Expected growth of 2.7-4.5%, driven by complex surgeries. Trends focus on robotic assistance.
Orthopedic Clinics: Projected growth of 2.9-4.8%, linked to outpatient care. Developments emphasize quick recovery.
Others: Anticipated growth of 2.6-4.3%, including specialty centers. Advances prioritize patient comfort.

Type Analysis
Hip Joints (Total Hip): Expected growth of 2.8-4.6%, valued for full replacement. Trends highlight durable materials.
Hip Joints (Partial Femoral Head): Projected growth of 2.7-4.4%, suited for partial damage. Advances focus on minimally invasive options.
Hip Joints (Hip Resurfacing): Anticipated growth of 2.6-4.3%, key for younger patients. Developments prioritize longevity.
Hip Joints (Revision Hip): Expected growth of 2.9-4.7%, linked to redo surgeries. Trends emphasize precision.
Knee Joints (Total Knee Replacement): Projected growth of 2.8-4.6%, dominant for osteoarthritis. Advances focus on robotics.
Knee Joints (Partial Knee Replacement): Anticipated growth of 2.7-4.5%, suited for localized damage. Trends highlight faster recovery.
Knee Joints (Revision Knee Replacement): Expected growth of 2.9-4.8%, key for implant failures. Developments prioritize durability.

Key Market Players
Leading firms include Zimmer Biomet, offering durable implants; Stryker, advancing with Mako robotics; Johnson & Johnson, enhancing joint tech; Exactech, focusing on precision; Smith+Nephew, improving outcomes; MicroPort Orthopedics, targeting affordability; CORENTEC, innovating with hip cups; Medacta International, optimizing alignment; Enovis Corporation, integrating ARVIS tech; and CONMED Corporation, supporting orthopedic solutions.

Porter's Five Forces Analysis
Threat of New Entrants: Moderate, due to high R&D and regulatory barriers, though niche innovators can emerge.
Threat of Substitutes: Moderate, with conservative treatments competing, but implants offer superior mobility.
Bargaining Power of Buyers: Moderate, as hospitals seek cost-effective, long-lasting implants, though brand loyalty limits leverage.
Bargaining Power of Suppliers: Low, with multiple material suppliers.
Competitive Rivalry: High, with firms competing on durability, robotics, and patient outcomes.

Market Opportunities and Challenges
Opportunities:
Osteoarthritis affecting 528 million globally and an aging population (2.1 billion over 60 by 2050) drive demand.
Rising sports injuries (3.5 million annually in the U.S.) and obesity (over 650 million worldwide) increase joint wear.
Innovations like Stryker’s Mako 4 and OXINIUM materials boost success rates above 95%, while emerging markets offer growth potential.
Challenges:
High costs of robotic systems limit adoption in developing regions.
Regulatory scrutiny for new materials slows entry.
Reimbursement variability affects accessibility.

Market News
In February 2024, CORENTEC received FDA clearance for its BENCOX Mirabo Z Cup hip implant.
In October 2023, Medacta introduced GMK SpheriKA for knee replacements.
In July 2022, Enovis acquired Insight Medical Systems, integrating ARVIS for joint surgery.